Therapeutic modification seen for 16 percent of patients with immune effector cell-associated neurotoxicity syndrome undergoing EEG
By Elana Gotkine HealthDay Reporter
FRIDAY, April 5, 2024 (HealthDay News) — For patients with immune effector cell-associated neurotoxicity syndrome (ICANS) due to chimeric antigen receptor (CAR) T-cell therapy, electroencephalogram (EEG) has the greatest therapeutic impact, according to a study published online March 19 in Blood Advances.
Mattéo Mauget, M.D., from the University Hospital of Rennes in France, and colleagues describe the role of magnetic resonance imaging (MRI), lumbar puncture (LP), and EEG in the management of ICANS in a cohort of real-life patients treated with CAR T-cell therapy. A total of 190 consecutive patients were treated with CAR T-cell therapy between August 2018 and January 2023.
The researchers found that 91 patients (48 percent) developed ICANS. MRI was performed in 78 percent of patients with ICANS; despite frequent abnormal findings, a therapeutic impact was only seen in 4 percent of patients. LP was performed in 47 percent of patients, leading to preemptive antimicrobial agent use in 7 percent of patients; no infections were detected. Fifty-one patients (56 percent) underwent systematic EEG, leading to therapeutic modifications in 16 percent of patients.
“Our study shows that diagnostic investigations recommended by international guidelines for ICANS management rarely result in therapeutic changes for MRI (4 percent) and LP (7 percent, all irrelevant), questioning the need for systematic assessment,” the authors write. “Our results highlight the need for novel ICANS management guidelines, which will limit the use of investigations to situations with a significant therapeutic impact and with an optimal risk-benefit ratio.”
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
